Iambic, a clinical-stage life science and know-how firm headquartered in San Diego, introduced that it has raised greater than $100 million in an oversubscribed financing spherical. The spherical drew participation from a broad group of recent and current traders spanning life sciences, development fairness, know-how, and sovereign wealth funds. Participating traders included Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.
The financing follows a interval of notable progress throughout Iambic’s pipeline and platform. The firm just lately shared medical knowledge for IAM1363 on the European Society for Medical Oncology Congress. The knowledge demonstrated anti-tumor exercise and a good security profile throughout each HER2-wild-type and HER2-mutated cancers in a number of affected person teams. Following that announcement, Iambic entered right into a analysis collaboration with Jazz Pharmaceuticals to judge the mix of zanidatamab with IAM1363 in sufferers with HER2-positive breast most cancers beforehand handled with Enhertu.
Additionally, Iambic introduced a collaboration earlier this 12 months with Revolution Medicines that gives entry to proprietary knowledge from Revolution Medicines and entry to Iambic’s NeuralPLexer protein-ligand construction prediction know-how. The firm additionally superior its Enchant multimodal transformer mannequin, which achieved sturdy efficiency throughout medical and preclinical predictive benchmarks.
Founded in 2020, Iambic has developed an AI-driven discovery and improvement platform integrating multimodal predictive modeling, physics-based molecular design, and automatic laboratory execution. The platform is designed to speed up discovery cycles and increase the druggable goal house. The firm expects its KIF18A and CDK2/4 applications to advance into medical improvement and anticipates extra partnerships and know-how collaborations.
KEY QUOTES:
“We are thrilled to have the support of many outstanding and committed investors who are partnering with Iambic to advance our mission of creating technologies to bring better medicines to patients.”
Tom Miller, PhD, Co-Founder and CEO, Iambic
“We are proud of the scientific and business progress Iambic has made across its pipeline, partnerships, and platform over this past year and view this fundraise as a testament to the exceptional work of the Iambic team. We look forward to continuing Iambic’s progress and anticipate our KIF18A and CDK2/4 programs entering the clinic as well as additional discovery and technology enablement collaborations in the near term.”
Tom Miller, PhD, Co-Founder and CEO, Iambic